Protocol·One

BPC-157 · For plantar fasciitis

BPC-157 for plantar fasciitis

Heel pain that won't go away with rest, ice, stretches. BPC-157?

S-Tier Recovery Moderate anecdotal

New to peptides? Start with the foundations ->

Why people use BPC-157 for plantar fasciitis

Heel pain that won't go away with rest, ice, stretches. BPC-157? The short answer: yes, this is one of the more-discussed uses for BPC-157 - but the evidence quality and the right protocol depend on what you're actually trying to fix.

This page covers what's known, what's not, and what the editorial take is for normal humans considering BPC-157 for plantar fasciitis.

What the evidence says

Evidence tier: Moderate anecdotal. Strong real-world anecdotal track record; mechanism extrapolates from related research.

  • Popular among runners and people on their feet all day.
  • Mechanism overlaps with general fascial repair, though no specific plantar fascia studies exist.
  • Most users pair with proper footwear correction and stretching protocol.

Protocol notes

Subcutaneous injection in foot or systemic. 250mcg/day for 4-6 weeks.

Always with a sports-medicine doctor, telehealth provider, or specialist sign-off. Self-experimenting on injection schedules without clinical input is the most common way people waste money and get hurt.

What to skip

  • Vendors without a Certificate of Analysis (COA). Random gym-bro vendors with no third-party testing. The peptide market has a quality-control problem; the answer is COA per peptide, every time.
  • Pre-mixed blends from non-pharmacy sources. Compounding pharmacies that produce pre-mixed combinations with COAs are fine. Random vendor "stack vials" are not.
  • Massively over-dosed protocols. More is rarely better with peptides. Receptor saturation is real. Stick to evidence-based dosing.

Where to go next

Subscribe to the dispatch

The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.

-> Subscribe free

Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine